BR0313092A - Sistema de liberação transdérmica aperfeiçoado - Google Patents

Sistema de liberação transdérmica aperfeiçoado

Info

Publication number
BR0313092A
BR0313092A BR0313092-4A BR0313092A BR0313092A BR 0313092 A BR0313092 A BR 0313092A BR 0313092 A BR0313092 A BR 0313092A BR 0313092 A BR0313092 A BR 0313092A
Authority
BR
Brazil
Prior art keywords
drug
amino
matrix
release system
functional
Prior art date
Application number
BR0313092-4A
Other languages
English (en)
Inventor
Mike Hannay
Dietrich Wilhelm Schacht
Hans-Michael Wolff
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of BR0313092A publication Critical patent/BR0313092A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Feeding, Discharge, Calcimining, Fusing, And Gas-Generation Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SISTEMA DE LIBERAçãO TRANSDéRMICA APERFEIçOADO". é provido um Sistema de Liberação Transdérmica (TDS) aperfeiçoado compreendendo uma camada de fundo inerte aos componentes da matriz, uma matriz auto-adesiva contendo uma droga amino funcional e uma lâmina ou folha protetora a ser removida antes da utilização, caracterizado pelo fato da matriz auto-adesiva consistir de um polímero semi-permeável sólido ou semi-sólido (1) em que foi incorporada uma droga amino funcional em sua forma de base livre, (2) que é saturado com a droga amino funcional e contém a dita droga como uma pluralidade de micro-reservatórios no interior da matriz, (3) que é altamente permeável à base livre da droga amino funcional, (4) que é impermeável à forma protonada da droga amino funcional, (5) em que o diâmetro máximo dos micro-reservatórios é menor que a espessura da matriz. O dito TDS provê um fluxo aumentado da droga amino funcional através da interface TDS/pele.
BR0313092-4A 2002-07-30 2003-07-28 Sistema de liberação transdérmica aperfeiçoado BR0313092A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02016864A EP1386604A1 (en) 2002-07-30 2002-07-30 Improved transdermal delivery system
PCT/EP2003/008319 WO2004012719A1 (en) 2002-07-30 2003-07-28 Improved transdermal delivery system

Publications (1)

Publication Number Publication Date
BR0313092A true BR0313092A (pt) 2005-06-21

Family

ID=30011092

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0313092-4A BR0313092A (pt) 2002-07-30 2003-07-28 Sistema de liberação transdérmica aperfeiçoado

Country Status (22)

Country Link
EP (2) EP1386604A1 (pt)
JP (1) JP4837915B2 (pt)
KR (1) KR101016914B1 (pt)
CN (1) CN100558350C (pt)
AT (1) ATE343380T1 (pt)
AU (1) AU2003266252B2 (pt)
BR (1) BR0313092A (pt)
CA (1) CA2490573C (pt)
CY (1) CY1105878T1 (pt)
DE (1) DE60309329T2 (pt)
DK (1) DK1524971T3 (pt)
ES (1) ES2273042T3 (pt)
HK (1) HK1083458A1 (pt)
IL (1) IL165917A (pt)
MX (1) MXPA05000349A (pt)
NO (1) NO334187B1 (pt)
NZ (1) NZ537476A (pt)
PL (1) PL376999A1 (pt)
PT (1) PT1524971E (pt)
SI (1) SI1524971T1 (pt)
WO (1) WO2004012719A1 (pt)
ZA (1) ZA200500255B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
JP5546013B2 (ja) * 2008-02-27 2014-07-09 久光製薬株式会社 貼付剤及び包装体
ES2536206T3 (es) * 2008-02-27 2015-05-21 Hisamitsu Pharmaceutical Co., Inc. Parche medicinal
ES2679800T3 (es) * 2009-12-22 2018-08-31 Lts Lohmann Therapie-Systeme Ag Polivinilpirrolidona para la estabilización de una dispersión sólida de la forma no cristalina de rotigotina
DE102011090178A1 (de) 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
ES2694662T3 (es) 2013-07-03 2018-12-26 Lts Lohmann Therapie-Systeme Ag Sistema terapéutico transdérmico con componente electrónico
EP4238580A3 (en) 2014-05-20 2023-10-25 LTS Lohmann Therapie-Systeme AG Transdermal delivery system including an interface mediator
CA2948220C (en) 2014-05-20 2023-06-20 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
CA2948219C (en) 2014-05-20 2023-04-04 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
FI3854388T3 (fi) 2020-01-24 2023-11-27 Luye Pharma Switzerland Ag Transdermaalinen hoitojärjestelmä, jossa on vaikuttava aine rotigotiini ja ainakin yksi ei-amiiniresistentti silikoniliima
EP3949956A1 (en) * 2020-08-06 2022-02-09 LTS Lohmann Therapie-Systeme AG Esketamine-suspension-tts

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736577A (en) * 1995-01-31 1998-04-07 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
FR2792529B1 (fr) * 1999-04-26 2001-09-28 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
IT1311696B1 (it) * 1999-06-22 2002-03-19 Zanussi Elettromecc Compressore del fluido frigorigeno azionato da un motore elettricoa frequenza di alimentazione variabile
JP2002045699A (ja) * 2000-08-08 2002-02-12 Mitsubishi Electric Corp 排ガス浄化用層状電気化学触媒
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
ATE364380T1 (de) * 2001-03-16 2007-07-15 Alza Corp Transdermales pflaster zur verabreichung von fentanyl
EP1372614A4 (en) * 2001-03-16 2007-10-31 Andrx Pharmaceuticals Llc SULPHONYL UREA FORMULATION WITH CONTROLLED RELEASE
DK1256340T3 (da) * 2001-05-08 2003-12-01 Sanol Arznei Schwarz Gmbh Forbedret transdermalt, terapeutisk system til behandlingen af Parkinsons sygdom
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine

Also Published As

Publication number Publication date
SI1524971T1 (sl) 2007-02-28
IL165917A (en) 2007-07-24
ZA200500255B (en) 2006-01-25
NO20050770L (no) 2005-02-11
DE60309329T2 (de) 2008-04-17
HK1083458A1 (en) 2006-07-07
EP1386604A1 (en) 2004-02-04
MXPA05000349A (es) 2005-03-31
WO2004012719A1 (en) 2004-02-12
AU2003266252B2 (en) 2008-11-20
PT1524971E (pt) 2007-01-31
EP1524971A1 (en) 2005-04-27
KR101016914B1 (ko) 2011-02-22
KR20050025638A (ko) 2005-03-14
PL376999A1 (pl) 2006-01-23
DE60309329D1 (de) 2006-12-07
IL165917A0 (en) 2006-01-15
CY1105878T1 (el) 2011-02-02
AU2003266252A1 (en) 2004-02-23
ES2273042T3 (es) 2007-05-01
CN1671365A (zh) 2005-09-21
JP2005535686A (ja) 2005-11-24
CN100558350C (zh) 2009-11-11
NZ537476A (en) 2007-08-31
JP4837915B2 (ja) 2011-12-14
ATE343380T1 (de) 2006-11-15
EP1524971B1 (en) 2006-10-25
DK1524971T3 (da) 2007-02-19
CA2490573C (en) 2011-06-07
NO334187B1 (no) 2014-01-13
CA2490573A1 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
NO20050472L (no) Forbedret transdermalt leveringssystem for administrering av rotigotin
BR0313092A (pt) Sistema de liberação transdérmica aperfeiçoado
AR097045A2 (es) Sistema terapéutico transdérmico
DE50103257D1 (de) Absorptionsmittel und kanalbildner enthaltende wirkstoffundurchlässige deckschicht oder abziehbare schutzschicht eines transdermalen therapeutischen systems
AR043248A1 (es) Sistema terapeutico transdermico estable a los rayos uv
AR093940A1 (es) Sistema de liberacion transdermica, metodo de preparacion
BR9910404A (pt) Sistema terapêutico transdérmico (tts) para administração transcutânea de pergolide por vários dias com um meio de fixar o tts sobre a pele
AR050621A1 (es) Sistema terapeutico transdermal con una capa adherente procedimiento para el siliconado de una capa de respaldo y empleo de la capa de respaldo
DK1613297T3 (da) Terapeutisk plaster med polysiloxanmatrix indeholdende capsaicin
WO2003018075A3 (de) Transdermales therapeutisches system mit fentanyl bzw. verwandten substanzen
DK0474647T3 (da) Fremgangsmåde og indretning til frigivelse af lægemidler til huden
DE60100937D1 (de) Pflaster für die lokale und transdermale verabreichung von wirkstoffen mit anionischen oder elektronen-anziehenden gruppen
AR054012A1 (es) Sistema terapeutico transdermico para la adminstracion de analgesicos
AR039137A1 (es) Unidad coherente de sistemas terapeuticos transdermicos separables
PT92903A (pt) Sistema terapeutico superficial contendo uma substancia activa antineoplastica,particularmente 5-fluorouracilo
ES2523663T3 (es) Sistema terapéutico transdérmico sólido con un agente absorbente de los rayos UV
BRPI0011135B8 (pt) sistema de ministração terapêutica transdérmica contendo agente neuroléptico
ATE368453T1 (de) Transdermale pflaster mit einer adhäsiven siliconmatrix stabilisiert mit methacryl copolymeren

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 9/70, A61K 31/38, A61P 25/16

Ipc: A61K 9/70 (2011.01), A61K 31/38 (2011.01), A61P 25

B25D Requested change of name of applicant approved

Owner name: UCB PHARMA GMBH (DE)

Free format text: NOME ALTERADO DE: SCHWARZ PHARMA AG

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL